Cochlear relieves Demant of loss-making implant division
Until now, Oticon Medical has been ”strategically important” for Demant, but hasn’t performed on par with expectations. Consequently, the subsidiary will be divested from its parent company, whose CEO says the deal made with the Australian firm is sound.
by christian bundgaard and albert rønning-andersson, translated by daniel pedersen
It is ostensibly not a growing business leg being removed from its parent company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Demant to divest hearing implant division to Cochlear
For subscribers
Demant lost ground at Veterans Affairs in March
For subscribers
